Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1 1
    Austria Belgium France Germany Greece Hungary +5
  • A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

    Recruiting

    2 1 1
    Investigated Drugs:
    Spain
  • Testing the Safety and Effects of TUB-030 in Patients with Advanced Head and Neck Cancer or Non-Small-Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    France Romania Spain
  • Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

    Recruiting

    3 1 1 1
    Belgium France Germany Greece Italy Poland +3
  • Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

    Recruiting

    2 1 1 1
    Belgium France Italy Spain
  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Hungary Poland Portugal Romania Spain
  • Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Greece Hungary Poland Romania Spain
  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Austria Estonia France Germany Ireland Italy +1
  • Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Spain
  • Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Austria Czechia Denmark France Germany Greece +3